Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 9/20 | 0.35 |
| ▸ | MAOB | P27338 | 4/20 | 0.33 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13758289 | 0.89 | F2R (0.34) | F2RMAOBBCHEMAOAACHE | |
| SCHEMBL13758419 | 0.84 | F2R (0.34) | F2RMAOBBCHEMAOAACHE | |
| SCHEMBL13971123 | 0.83 | F2R (0.36) | F2RMAOBBCHEMAOAACHE | |
| SCHEMBL13758251 | 0.82 | F2R (0.42) | F2RMAOBBCHEMAOAACHE | |
| SCHEMBL13758367 | 0.82 | F2R (0.31) | F2R | |
| SCHEMBL13758362 | 0.82 | F2R (0.42) | F2RMAOBBCHEMAOAACHE | |
| SCHEMBL13758250 | 0.82 | F2R (0.41) | F2RMAOBBCHEMAOAACHE | |
| SCHEMBL13758391 | 0.82 | F2R (0.31) | F2RMAOBBCHEMAOAACHE | |
| SCHEMBL13758423 | 0.82 | F2R (0.38) | F2RMAOBBCHEMAOAACHE | |
| SCHEMBL13758377 | 0.81 | F2R (0.43) | F2RMAOBBCHEMAOAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215795-A1 | CYCLIC AMIDINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215795-A1 | CYCLIC AMIDINE DERIVATIVES | H1-10, H1-3, H1-4 | F2R 1447/4885MAOB 2563/4885BCHE 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.